The ACCC has won its request for an injunction blocking rail freight operator Aurizon from shutting its intermodal business down while a competition lawsuit the regulator filed over Aurizon’s proposed sale of the business to Pacific National makes its way through the court.
One of Australia’s largest debt collectors, ACM Group, harassed and coerced vulnerable customers — including a stroke victim — by bombarding them with phone calls and making empty threats of litigation, the Federal Court found Monday.
Two generic drug makers have lost their bid for confidential documents related to Neurim Pharmaceuticals’ patents covering sleep drug Circadin, with a court ruling legal professional privilege was waived in a phone conversation between a DLA Piper lawyer and the company’s founder.
A judge has served up a loss for Domino’s Pizza in its ongoing IP battle with Australian tech startup Precision Tracking, dismissing the company’s bid to bolster its case with an Uber patent.
Triclops Technologies has filed an appeal less than one month after the Federal Court dismissed its case alleging a rival infringed its patent for an industrial machine safety system that uses laser fields to detect hazards, but found the patent was valid.
Two GPS tracking patents at the heart of a David vs. Goliath battle between Domino’s and a Sydney-based startup were foreshadowed by a patent owned by Uber, the pizza chain giant told a court Friday.
Three generic drug manufacturers cannot claim damages for an injunction barring the release of cheaper versions of Effexor-XR, even if the injunction was later overturned, pharmaceutical giant Wyeth told a judge on day two of a six-week trial over its blockbuster antidepressant.
The High Court has rejected a bid by biopharmaceutical company Samsung Bioepis Australia to challenge a ruling granting Pfizer preliminary discovery for a potential patent infringement case over autoimmune drug Enbrel.
Pharmaceutical giant Wyeth’s has launched an “ambush” at the beginning of a trial after a nine-year long battle against several generic drug makers, alleging infringement of a second patent for its blockbuster Effexor-XR, a judge heard Monday.
A decade-long courtroom battle over a patent for Effexor-XR that delayed the release of cheap versions of the anti-depressant is at the centre of a trial starting Monday in Sydney pitting four generic drug makers against pharmaceutical giant Wyeth.